- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01747499
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Missouri
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Patients must meet the following criteria within 30 days prior to Day 0 unless otherwise noted.
Phase I: Diagnosis of any hematological malignancy listed below (excluding myelofibrosis) in remission or with stable minimal residual disease
- Acute myelogenous leukemia (AML) in 1st or subsequent remission or in relapse after any remission
- Acute lymphoblastic leukemia (ALL) in 1st or subsequent remission or in relapse after any remission
- Myelodysplastic syndrome either intermediate 1 or 2, or high risk by the International Prognostic Scoring System
- Chronic myelogenous leukemia (CML) in accelerated or second chronic phase
- Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete remission, partial remission, or refractory relapse
- Chronic lymphocytic leukemia (CLL), Rai Stage 2-4, failing at least 2 prior regimens
- Multiple myeloma (MM), Stage 2-3
- Myeloproliferative disorder or neoplasm
- Phase II: Diagnosis of AML in remission 1 or 2 or a diagnosis of myelodysplastic syndrome either intermediate 1 or 2, or high risk by the International Prognostic Scoring System.
- Patients with MDS must be transplant candidates by current clinical standards.
- Patients who have been treated with hypomethylating agents prior to entering the study are eligible.
- Must have matched unrelated donor (8 of 8 HLA match at A, B, C, and DR loci) by high resolution DNA typing
- Must have donor peripheral blood stem cells mobilized by NMDP standards. No bone marrow donors.
- Must have 2-8 x 10^6 CD34+ cells/kg (recipient weight) infused on Day 0.
- Must have at least one additional aliquot of >=1 x 10^6 CD34/kg cryopreserved cells stored at the time of transplant.
Must receive a myeloablative or reduced intensity conditioning regimen for SCT as defined by the CIBMTR
- Cyclophosphamide and single dose total body irradiation
- Fludarabine and busulfan
- Fractionated TBI and cyclophosphamide
- Busulfan and cyclophosphamide
- Must be able to receive GVHD prophylaxis with tacrolimus and methotrexate.
- Must be ≥ 18 yrs old and ≤ 70 yrs old. Azacitidine is not approved by the FDA for use in children.
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Must have laboratory results indicating:
- Total bilirubin < 2.0 mg/dl, unless a diagnosis of Gilbert's disease
- AST/ALT ≤ 3 X the upper limit of institutional normal
- Serum creatinine ≤ 2.0 mg/dl
- Patient must have ability to understand and willingness to provide written informed consent prior to participation in the study and any related procedures being performed.
- The effects of azacitidine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because category D agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of childbearing age must have a negative serum pregnancy test (ß-human chorionic gonadotropin) within 72 hours prior to initiating the conditioning regimen and be willing to not become pregnant by using effective contraception while undergoing treatment and for at least 3 months after the last dose of azacitidine.
- Men must be willing not to father a new child while receiving therapy. They must use an effective barrier method of contraception during the study and for 3 months following the last dose.
Exclusion Criteria:
- Must not have myelofibrosis or other disease known to prolong neutrophil engraftment to > 28 days after transplant.
- Must not be receiving any other investigational agents within 14 days of first dose of azacitidine (Day 7).
Must not have myeloablative conditioning as defined below:
- TBI < or = Gy +/- purine analog
- Flu + Cy +/- ATG
- Flu + AraC + Ida
- Cladribine + AraC
- Total Lymphoid Irradiation + ATG
- Must not receive antithymocyte globulin as part of pre-transplant conditioning regimens. Antithymocyte globulin is excluded due to its potential impact on modulating the incidence of GvHD or GvL.
- Must not have uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
- Must not be pregnant or breastfeeding. Pregnant women are excluded from this study because azacitidine is a Category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with azacitidine, breastfeeding should be discontinued if the mother is treated azacitidine. These potential risks may also apply to other agents used in this study.
- Must not have a known or suspected hypersensitivity to azacitidine, mannitol, or compounds of similar composition to azacitidine..
- Must not have an advanced malignant hepatic tumor.
- Must not be HIV, HBV, or HCV positive.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Cohort 1
Conditioning treatment Transplant on Day 0 15 mg/m^2 azacitidine Days 7-11 15 mg/m^2 azacitidine Days 35-39 15 mg/m^2 azacitidine Days 63-67 15 mg/m^2 azacitidine Days 91-95 |
Autres noms:
|
Expérimental: Cohort 2
Conditioning treatment Transplant on Day 0 30 mg/m^2 azacitidine Days 7-11 30 mg/m^2 azacitidine Days 35-39 30 mg/m^2 azacitidine Days 63-67 30 mg/m^2 azacitidine Days 91-95 |
Autres noms:
|
Expérimental: Cohort 3
Conditioning treatment Transplant on Day 0 37.5 mg/m^2 azacitidine Days 7-11 37.5 mg/m^2 azacitidine Days 35-39 37.5 mg/m^2 azacitidine Days 63-67 37.5 mg/m^2 azacitidine Days 91-95 |
Autres noms:
|
Expérimental: Cohort 4
Conditioning treatment Transplant on Day 0 45 mg/m^2 azacitidine Days 7-11 45 mg/m^2 azacitidine Days 35-39 45 mg/m^2 azacitidine Days 63-67 45 mg/m^2 azacitidine Days 91-95 |
Autres noms:
|
Expérimental: Phase II Cohort
Conditioning treatment Transplant on Day 0 Dose determined in Phase I - 45 mg/m^2 azacitidine Days 7-11 Dose determined in Phase I - 45 mg/m^2 azacitidine Days 35-39 Dose determined in Phase I - 45 mg/m^2 azacitidine Days 63-67 Dose determined in Phase I - 45 mg/m^2 attitudinize Days 91-95 |
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Phase I: to Determine the Maximum Tolerated Dose (MTD) of Azacitidine in Patients Undergoing Matched (8 Out of 8) Unrelated Donor Transplant for Any Hematological Malignancy in Remission or With Stable Disease.
Délai: 28 days
|
The MTD is defined as the dose level immediately below the dose level at which patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity.
|
28 days
|
Phase II: Number of Participants With Grades II-IV Acute GvHD
Délai: Day +180
|
GVHD rate and severity will be assessed based on modified Glucksberg criteria.
Grade II-IV and III-IV aGVHD in first 180 days after transplant will be assessed.
|
Day +180
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Rate of Grades III-IV aGVHD at Day +180.
Délai: Day +180
|
GVHD rate and severity will be assessed based on modified Glucksberg criteria.
|
Day +180
|
Overall Survival as Measured by Number of Participants Alive at 1 Year After Transplant
Délai: One year after transplant
|
Date of transplant to the date of death from any cause.
|
One year after transplant
|
Treatment-related Mortality
Délai: Day +140
|
Death that results from a transplant procedure-related complication (e.g.
infection, organ failure, hemorrhage, GVHD) rather than from relapse of the underlying disease or an unrelated cause.
|
Day +140
|
Number of Participants Who Relapsed Within the First Year of Transplant
Délai: Within the first year of transplant
|
Recurrence of the original malignant disease after transplantation.
The time to relapse is the time to the first observation of hematologic, radiographic, or cytogenetic changes, which result in characterization as relapse.
|
Within the first year of transplant
|
Rate of Chronic GvHD
Délai: One year after transplant
|
One year after transplant
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Mark A. Schroeder, M.D., Washington University School of Medicine
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Maladies de la moelle osseuse
- Maladies hématologiques
- Leucémie, Lymphoïde
- Syndromes myélodysplasiques
- Leucémie
- Leucémie myéloïde
- Leucémie, myéloïde, aiguë
- Leucémie-lymphome lymphoblastique à cellules précurseurs
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Antimétabolites, Antinéoplasique
- Antimétabolites
- Agents antinéoplasiques
- Azacitidine
Autres numéros d'identification d'étude
- 201303012
- 1P50CA171963-01A1 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .